Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00342381 (ClinicalTrials.gov)	June 2006	20/6/2006	Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation	Fatigue in Multiple Sclerosis: Evaluated With 3 Tesla MRI and Transcranial Magnetic Stimulation	Multiple Sclerosis;Fatigue	Drug: 3,4-diaminopyridine;Drug: Placebo	University of Aarhus	The Danish Multiple Sclerosis Society	Completed	18 Years	55 Years	Both	120	Phase 2	Denmark
2	NCT00190268 (ClinicalTrials.gov)	February 2005	13/9/2005	Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis	Multicentric Study, Comparative, Randomized, in Double Knowledge of the Effectiveness (Versus Placebo) of a Salt Of 3,4 - Diaminopyridine in the Treatment of Tiredness During the Multiple Sclerosis	Multiple Sclerosis	Drug: 3,4-diaminopyridine	Assistance Publique - Hôpitaux de Paris	NULL	Completed	18 Years	60 Years	Both	126	Phase 3	France